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An investigation of the antimicrobial impact of drug
combinations against Mycobacterium tuberculosis strains*
Mine HOŞGÖR LİMONCU, Şafak ERMERTCAN, Bayrı ERAÇ, Hüseyin TAŞLI

Aim: To investigate the in vitro activity of linezolid and ofloxacin in combination with first-line antituberculosis agents
(isoniazid and rifampicin) against M. tuberculosis strains. The use of combinations that include fluoroquinolones and
oxazolidinone is now being considered for the treatment of resistant Mycobacterium tuberculosis strains.
Materials and methods: The minimum inhibitory concentrations of the test drugs were determined by the standard
agar dilution method. The interaction of drug combinations was investigated by time-kill method.
Results: A total of 9 M. tuberculosis strains were used in this study, 5 of which were multidrug-resistant (MDR) and 4
of which were not. The studied 2-agent drug combinations were indifferent in 4 MDR and 2 non-MDR M. tuberculosis
strains, respectively. Additive interaction was observed between isoniazid and ofloxacin in one MDR M. tuberculosis
strain on the eighth day and in one non-MDR strain on the third, fifth, and eighth days, respectively, while rifampicin
and linezolid exhibited additive interaction in another non-MDR strain on the eighth day.
Conclusion: Although many previous studies have found a synergistic activity with similar drug combinations, only
additive interaction was observed in some of the M. tuberculosis strains involved in this study.
Key words: Mycobacterium tuberculosis, drug combinations, ofloxacin, linezolid

Mycobacterium tuberculosis kökenleri üzerine ilaç kombinasyonlarının
antimikrobiyal etkisinin araştırılması
Amaç: Son yıllarda dirençli Mycobacterium tuberculosis kökenlerinin tedavisinde florokinolon ve oksazolidinon grubu
ilaçların da bulunduğu kombinasyonların kullanımı gündeme gelmiştir. Bu çalışmada, M. tuberculosis kökenleri üzerine
birinci seçenek antitüberküloz ilaçlardan izoniazid ve rifampisinin, linezolid ve ofloksasin ile kombinasyonunun
etkinliğinin araştırılması amaçlandı.
Yöntem ve gereç: Antimikrobiyallerin minimal inhibitör konsantrasyon değerleri agar proporsiyon yöntemi ile
belirlendi. İlaç kombinasyonlarının etkileşimleri zamana bağlı öldürme eğrisi yöntemi ile araştırıldı.
Bulgular: Beşi “çok ilaca dirençli” (ÇİD), dördü ÇİD olmayan toplam dokuz M. tuberculosis kökeni incelendi. ÇİD
M. tuberculosis kökenlerinden dördünde, ÇİD olmayan kökenlerin ise ikisinde, incelenen antibiyotik kombinasyonları
arasında etkileşim saptanmadı. Bir ÇİD M. tuberculosis kökeninde, sekizinci günde izoniazid-ofloksasin arasında aditif
etki belirlendi. ÇİD olmayan kökenlerin birinde, üçüncü, beşinci ve sekizinci günlerde izoniazid-ofloksasin arasında,
diğer bir duyarlı kökende ise sekizinci günde rifampisin-linezolid arasında aditif etki görüldü.
Sonuç: Bu konuda sınırlı sayıdaki çalışmaların çoğunda benzer ilaç kombinasyonlarında sinerjistik etki saptanmasına
rağmen, bu çalışmada bazı kökenlerde sadece aditif etkileşim gözlenmiştir.
Anahtar sözcükler: Mycobacterium tuberculosis, ilaç kombinasyonları, ofloksasin, linezolid
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Introduction
Despite being one of the oldest diseases,
tuberculosis is still a global epidemic. The mortality
rate of tuberculosis is more than 90% in developing
countries. Factors such as the high prevalence of human
immunodeficiency virus (HIV)-infected patients,
the emergence of multidrug-resistant (MDR) cases,
and outbreaks involving MDR strains in hospitals
have decreased the efficacy of antituberculosis drugs.
Isoniazid (INH), rifampicin (RIF), ethambutol
(ETB), streptomycin (SM), and pyrazinamide
(PZA) are first-line antituberculosis drugs. Recently,
however, the number of Mycobacterium tuberculosis
strains resistant to at least INH and RIF, a resistance
which is known as MDR, has increased. Second-line
drugs may be used as alternatives for the treatment
of infections caused by MDR strains, but these drugs
tend to be neither very effective nor cheap. Moreover,
many have toxic side effects (1-5).
A failure to effectively treat MDR tuberculosis can
lead to the generation of extensively drug-resistant
(XDR) M. tuberculosis strains. Recent outbreaks of
MDR and XDR tuberculosis have led to a demand
for the discovery of new antituberculosis drugs
(4,6). Fluoroquinolones have emerged as alternative
antituberculosis drugs, especially for the treatment
of infections due to MDR M. tuberculosis strains.
Fluoroquinolones inhibit topoisomerase II (DNA
gyrase) in M. tuberculosis. A notable property of
fluoroquinolones relates to their ability to penetrate
into macrophages and to exert intracellular
mycobactericidal activity. Among the drugs that have
shown promising activity in the treatment of MDR
tuberculosis is linezolid (LIN). It is a member of the
oxazolidinone class and its mechanism of action
involves the inhibition of protein synthesis (4,5,7-9).
To prevent the emergence of drug resistance
and to lower the toxic side effects, combinations of
different antimycobacterial agents are used. Some of
the in vitro studies investigating the efficacy of the
new drugs use only one antibiotic, but the activity
of these new compounds must also be studied in
combination with classic drugs (10,11). Hence, we
aimed to evaluate the in vitro activity of ofloxacin
(OFX), as a member of the fluoroquinolones, and
LIN in combination with first-line antituberculosis
agents (INH and RIF) against M. tuberculosis strains.
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Materials and methods
Strains and determination of MIC values
After being isolated from various clinical samples
(1 strain per patient), 9 M. tuberculosis strains
were investigated in the Tuberculosis Laboratory
of the Department of Microbiology and Clinical
Microbiology at Ege University’s Faculty of Medicine.
Using the agar dilution method, the susceptibility
patterns of all isolates were studied with regard to
first-line antituberculosis drugs (12). Out of a total of
9 strains, 5 were found to be MDR strains.
OFX (Koçak Ltd. Şti.), LIN (Pfizer Inc.), INH, and
RIF (Sigma) stock solutions were prepared in distilled
water at a concentration of 1 mg/mL. Aliquots of
these solutions were frozen at –20 °C until used.
The agar dilution method was performed as
described by the Clinical and Laboratory Standards
Institute (CLSI, formerly NCCLS) (12), and H37Rv
(ATCC 27294) was used as the control strain. Briefly,
after sterilization, Middlebrook (MB) 7H10 agar
medium (BD & Difco) was cooled to 50-55 °C and
supplemented with MB OADC (oleic acid, albumin,
dextrose, and catalase) (BD) (10%, vol/vol). The
appropriate volumes of diluted LIN, OFX, INH, and
RIF stock solutions were incorporated into aliquots
of 7H10 agar medium in order to achieve the desired
final concentrations of LIN (0.03-4 mg/L), OFX
(0.06-4 mg/L), INH (0.025-128 mg/L), and RIF
(0.03-128 mg/L). Once the drugs were introduced
to the media, the solutions were dispensed quickly
into sterile plastic bipartite petri dishes, allowed to
solidify, and either used immediately or stored at 4 °C
until used. For each strain, one agar medium without
drug was also prepared as the growth control. The
standard inoculum of each isolate was adjusted to an
equal density of 1 McFarland standard by diluting the
initial inoculum with MB 7H9 broth (BD & Difco).
Final suspensions were prepared using 10–2 and 10–4
dilutions of the standardized suspensions with MB
7H9 broth. On each part of the agar plates, 100 μL
of the diluted inoculum was placed, both with and
without drugs. All plates were sealed and incubated
at 37 °C in 5%-10% CO2 for 3 weeks. The MIC of each
isolate was determined to be the lowest concentration
of an antibiotic that inhibited >99% of the colonies
growing on the drug-free control (12).
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Time-kill study
The in vitro activity of OFX and LIN in
combination with first-line antituberculosis agents
(INH and RIF) against M. tuberculosis strains was
determined by use of the time-kill method (6,13). The
isolates were first grown to a turbidity of 1 McFarland
standard in MB 7H9 broth supplemented with
OADC for 7-10 days at 37 °C. The cell suspensions
were then adjusted to give a final concentration of 105
CFU (colony forming unit)/mL in the culture broth.
The actual number of CFUs per milliliter in each
tube at time zero was determined by plating a 0.1
mL fraction of dilutions prepared in MB 7H9 broth.
Solutions of single antimicrobial agents and those in
combinations were prepared to achieve the MICs of
the respective agents. Cell suspensions were added to
both the test and control tubes and incubated at 37
°C in 5%-10% CO2 atmosphere. During incubation,
a 0.1-mL sample was removed from these tubes on
the initial day, as well as on the third, fifth, and eighth
days, and spread onto MB 7H10 agar containing
OADC. The plates were incubated at 37 °C for 21

days and the colonies were counted, a procedure
that was repeated twice. Synergy or antagonism was
defined as a decrease or increase of 2 or more in
log10 CFU/mL when compared with the figures for
the respective single agents. A decrease in CFU/mL
between 2 log10 and 1 log10 was evaluated as additive
interaction (6,13).
Results
The MIC values for INH, RIF, LIN, and OFX
are shown in the Table, as are the origins of the M.
tuberculosis strains. The studied 2-agent antibiotic
drug combinations were indifferent in 4 of the MDR
M. tuberculosis strains and in 2 of the non-MDR
strains. Additive interaction was observed between
INH and OFX in one MDR M. tuberculosis strain
on the eighth day (Figure 1), while the same effect
was found between INH and OFX in one non-MDR
strain on the third, fifth, and eighth days, respectively.
A similar additive interaction was also observed
between RIF and LIN in another non-MDR strain on
the eighth day (Figure 2).

Table. The origins of M. tuberculosis strains and MIC values for INH, RIF, OFX, and LIN.
MIC (mg/L)
Strains

Origin
INH

RIF

OFX

LIN

MDR M. tuberculosis strains
1

Sputum

2

128

0.5

0.06

2

Urine

8

16

0.5

0.5

3

Sputum

8

8

1

0.5

4

Cerebrospinal fluid

64

32

0.5

0.5

5

Bronchial aspirate

8

4

0.5

0.5

1

Abscess

0.5

0.125

0.5

0.5

2

Sputum

0.05

0.125

1

0.06

3

Sputum

0.5

0.06

1

0.5

4

Bronchial aspirate

0.5

0.25

0.5

0.25

Non-MDR M. tuberculosis strains

Multidrug-resistant: MDR; minimum inhibitory concentration: MIC;
isoniazid: INH; rifampicin: RIF; ofloxacin: OFX; linezolid: LIN.
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Figure 1. Time-kill curve results of MDR strain 4 at the MIC values of antibiotics.
Isoniazid: INH; rifampicin: RIF; ofloxacin: OFX; linezolid: LIN; RIF + LIN:
no interaction; INH + LIN: no interaction; RIF + OFX: no interaction; INH +
OFX: additive.
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Figure 2. Time-kill curve results of non-MDR strain 2 at the MIC values of antibiotics.
Isoniazid: INH; rifampicin: RIF; ofloxacin: OFX; linezolid: LIN; RIF + LIN:
additive; INH + LIN: no interaction; RIF + OFX: no interaction; INH + OFX:
no interaction.

Discussion
The treatment of multidrug-resistant tuberculosis
strains is extremely difficult, and a well-equipped
laboratory is needed to determine drug resistance in
these strains. Second-line antituberculosis drugs are
used in the treatment of infections caused by strains
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that are resistant to first-line drugs. However, the
effectiveness of these drugs is low, they are not cost
effective, and they may also have toxic side effects.
Therefore, tuberculosis chemotherapy requires
new therapy options that have both different action
mechanisms and bactericidal effects (7,10). LIN,
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which inhibits the protein synthesis in bacteria, and
OFX, a DNA gyrase enzyme inhibitor, are extremely
effective against resistant tuberculosis strains.
They have therefore recently acquired considerable
importance in the treatment of MDR M. tuberculosis
strains (1,5,14-16).
In recent years, a variety of in vitro studies
have been conducted that have demonstrated
the effectiveness of both LIN and OFX against
tuberculosis. However, these drugs have to be
used in combination with other antituberculosis
drugs in order to prevent resistance development
and to control the tuberculosis epidemic. These
combinations do not only shorten the duration
of treatment of the active disease but also destroy
the latent M. tuberculosis strains in asymptomatic
patients (10,17,18).
Rodriguez Diaz et al. (10) examined 16 M.
tuberculosis strains and determined the synergism
between INH and fluoroquinolones in 9 of the 10
INH-sensitive strains and in only 1 of the 6 INHresistant strains. A synergistic effect between INH
and LIN was observed in 3 of the 10 INH-sensitive
strains while no interaction was seen in the INHresistant strains. Synergistic activity was observed
between RIF and LIN in 5 and between RIF and
fluoroquinolones in 4 of the 15 RIF-sensitive strains.
Such an interaction was not determined in the RIFresistant strains, however. In the study conducted
with strains in which the MDR characteristic was not
specified, it was observed that the above mentioned
combinations led to a synergistic effect primarily in
the INH- and RIF-sensitive strains. A similar effect
was observed between INH and fluoroquinolones
in the 1996 study of Rastogi et al. (7), performed
on INH-sensitive strains. Although synergism was
not determined in this study, additive interaction
was detected between INH and OFX in 3 strains,
including 1 MDR strain.
In a study conducted in 2005 (11), the interaction
between first-line antituberculosis drugs and
28 different agents was investigated using the
3-dimensional checkerboard method. The study
made use of 10 different M. tuberculosis strains,
including 7 that were MDR strains. Using the
checkerboard method, it was concluded that a
potential synergism exists between INH and RIF and

a group of antimicrobials including agents such as
fluoroquinolones and clarithromycin. This finding
was confirmed by the time-kill curve method.
Subsequently, the interaction of these selected
agents with RIF or INH was investigated using
the 2-dimensional checkerboard technique and
no synergism or antagonistic effect was observed.
These results are consistent with the time-kill curve
obtained for this study.
In a study conducted by Lu and Drlica (19) to
investigate the interaction between moxifloxacin,
a C-8 methoxy-substituted fluoroquinolone, and
first-line antituberculosis drugs, they reported that
an additive effect was present between INH and
moxifloxacin and that the same interaction was also
observed between lower concentrations of RIF and
moxifloxacin. Generally, C-8 methoxy- or chlorosubstituted agents from the fluoroquinolone group,
such as moxifloxacin, gatifloxacin, and sitafloxacin,
have been used in studies in which a synergistic effect
was found between fluoroquinolones and first-line
antituberculosis drugs (11,19). In this study, however,
OFX, an effective alternative antituberculosis drug,
was used and only additive interactions were observed
in some strains. It has been reported in some studies
that the C-8 methoxy- and chloro-fluoroquinolones
demonstrate a better antituberculosis activity
compared to classical fluoroquinolones (11).
In a study investigating the effectiveness of the
combination of LIN with first-line antituberculosis
drugs, synergy was determined in INH- and RIFsusceptible strains, while no interaction was observed
in RIF- or INH-resistant strains (10). Although the
synergistic activity of OFX and LIN in combination
with first-line antituberculosis agents was reported
in most studies, indifferent or additive interactions
were detected in this study. Because antagonism was
not found, it was concluded that the studied 2-agent
drug combinations could be used in the therapy of
clinically suitable cases.
Since the data about this topic is limited, further
studies investigating the antituberculosis effectiveness
of combinations containing LIN and fluoroquinolones
are needed. Additionally, an increase in the number
of studies investigating the in vivo effectiveness
of antituberculosis drug combinations would add
clarity to the general knowledge in this field.
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